ZIF-8 with cationic defects toward efficient 125I2 uptake for in vitro radiotherapy of colon cancer

Xin-Xin Tian; Yi-Tong Liu; Yan Li; Xin-Yu Qiu; Wen-Hua Zhang; David J Young; Qiu Chen

doi:10.1039/d1cc07304d

ZIF-8 with cationic defects toward efficient ¹²⁵I₂ uptake for in vitro radiotherapy of colon cancer

Chem Commun (Camb). 2022 Jun 16;58(49):6942-6945. doi: 10.1039/d1cc07304d.

Authors

Xin-Xin Tian¹, Yi-Tong Liu², Yan Li¹, Xin-Yu Qiu², Wen-Hua Zhang¹, David J Young³, Qiu Chen¹

Affiliations

¹ College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China. whzhang@suda.edu.cn.
² State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection (SRMP) of Soochow University, Suzhou 215123, China. happyqiu@suda.edu.cn.
³ College of Engineering, Information Technology & Environment, Charles Darwin University, Darwin, Northern Territory 0909, Australia.

PMID: 35640157
DOI: 10.1039/d1cc07304d

Abstract

Introducing 2,3-dimethyl-1H-imidazol-3-ium iodide (Dmim) as a monodentate ligand during the preparation of ZIF-8 yields ZIF-8 + (50) and ZIF-8 + (38) with cationic 'missing linker' defects. ZIF-8 + (38) adsorbs ¹²⁵I₂ and the resulting radioactive host-guest complex exhibits in vitro cytotoxicity comparable to that of Na¹²⁵I against colon cancer cell line CT26.

MeSH terms

Cations
Colonic Neoplasms* / radiotherapy
Humans
Iodine Radioisotopes
Zeolites* / pharmacology

Substances

Cations
Iodine Radioisotopes
Zeolites
Iodine-125